Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
Discovery of the epidermal growth receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements has expanded the therapeutic landscape in non-small cell lung cancer (NSCLC). Survival outcomes for patients with these mutations have improved dramatically with EGFR and ALK ty...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Association of Physical Chemists (IAPC)
2016-10-01
|
| Series: | ADMET and DMPK |
| Subjects: | |
| Online Access: | http://pub.iapchem.org/ojs/index.php/admet/article/view/337 |